Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups

Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas

(2015) Yuchen Jiao et al.   Oncotarget

The genetic landscape of anaplastic astrocytoma

(2015) Patrick J. Killela et al.   Oncotarget

Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas

(2015) Patrick J. Killela et al.   Oncotarget

Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma

(2014) Benedikt Wiestler et al.   ACTA NEUROPATHOLOGICA

Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma

(2014) Felix Sahm et al.   ACTA NEUROPATHOLOGICA

International Society of Neuropathology-Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading

(2014) David N. Louis et al.   BRAIN PATHOLOGY

Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling

(2014) Guido Reifenberger et al.   INTERNATIONAL JOURNAL OF CANCER

Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation ofIDH

(2014) J. Gregory Cairncross et al.   JOURNAL OF CLINICAL ONCOLOGY

Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial

(2014) B. Wiestler et al.   NEURO-ONCOLOGY

ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis

(2013) Benedikt Wiestler et al.   ACTA NEUROPATHOLOGICA

Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system

(2013) Christian Koelsche et al.   ACTA NEUROPATHOLOGICA

Molecular neuro-oncology in clinical practice: a new horizon

(2013) Michael Weller et al.   LANCET ONCOLOGY

Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma

(2013) David T W Jones et al.   NATURE GENETICS

Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation

(2013) W. Wick et al.   NEUROLOGY

Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations

(2012) Xiao-Yang Liu et al.   ACTA NEUROPATHOLOGICA

The Definition of Primary and Secondary Glioblastoma

(2012) H. Ohgaki et al.   CLINICAL CANCER RESEARCH

Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402

(2012) Gregory Cairncross et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951

(2012) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Mining SOM expression portraits: feature selection and integrating concepts of molecular function

(2012) Henry Wirth et al.   BioData Mining

Expression cartography of human tissues using self organizing maps

(2011) Henry Wirth et al.   BMC BIOINFORMATICS

Gene expression in oligodendroglial tumors

(2011) Elisabeth J. Shaw et al.   CELLULAR ONCOLOGY

Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing

(2010) Jörg Felsberg et al.   ACTA NEUROPATHOLOGICA

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

(2010) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective

(2010) Martin J. van den Bent   ACTA NEUROPATHOLOGICA

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

Update on molecular findings, management and outcome in low-grade gliomas

(2010) T. David Bourne et al.   Nature Reviews Neurology

The Proneural Molecular Signature Is Enriched in Oligodendrogliomas and Predicts Improved Survival among Diffuse Gliomas

(2010) Lee A. D. Cooper et al.   PLoS One

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas

(2009) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma Patients

(2009) J. Felsberg et al.   CLINICAL CANCER RESEARCH

Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network

(2009) Michael Weller et al.   JOURNAL OF CLINICAL ONCOLOGY

NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide

(2009) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

 -Internexin expression identifies 1p19q codeleted gliomas

(2009) F. Ducray et al.   NEUROLOGY

Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile

(2008) Francois Ducray et al.   Molecular Cancer